Merck's Keytruda meets PFS endpoint in endometrial cancer trial

July 15, 2026 6:45 AM

Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-C93 trial evaluating Keytruda (pembrolizumab) as monotherapy met its primary endpoint of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found